John McGee, Ph.D.

John McGee brings to FogPharma more than a decade of experience in developing and applying new discovery and optimization technologies for helically constrained (Helicon) peptide therapeutics.

Prior to joining FogPharma, John was a postdoctoral research fellow at Harvard University, where he worked in the laboratory of Dr. Greg Verdine. At Harvard, he performed foundational work on both the de novo screening and multiplexing platforms that now form the core of FogPharma’s rapid early discovery engine. These studies also led to the development of the tandem paired-helix Griptide platform, now licensed by FogPharma; John made the key discovery of Griptides that bind a range of active RAS isoforms and oncogenic mutants with picomolar affinity.

John holds a B.S. in chemistry from Stanford University, where he worked in the laboratory of Dr. Eric Kool, and a Ph.D. in biochemistry from Harvard University, where he studied with Dr. Greg Verdine.